Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback